Literature DB >> 10567715

G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells.

W Y Siu1, C H Yam, R Y Poon.   

Abstract

Cell cycle arrest after different types of DNA damage can occur in either G1 phase or G2 phase of the cell cycle, involving the distinct mechanisms of p53/p21(Cip1/Waf1) induction, and phosphorylation of Cdc2, respectively. Treatment of asynchronously growing Swiss3T3 cells with the chemotherapeutic drug adriamycin induced a predominantly G2 cell cycle arrest. Here we investigate why Swiss3T3 cells were arrested in G2 phase and not in G1 phase after adriamycin-induced damage. We show that adriamycin was capable of inducing a G1 cell cycle arrest, both during the G0-G1 transition and during the G1 phase of the normal cell cycle. In G0 cells, adriamycin induced a prolonged cell cycle arrest. However, adriamycin caused only a transient cell cycle delay when added to cells at later time points during G0-G1 transition or at the G1 phase of normal cell cycle. The G1 arrest correlated with the induction of p53 and p21(Cip1/Waf1), and the exit from the arrest correlated with the decline of their expression. In contrast to the G1 arrest, adriamycin-induced G2 arrest was relatively tight and correlated with the Thr-14/Tyr-15 phosphorylation of cyclin B-Cdc2 complexes. The relative stringency of the G1 versus G2 cell cycle arrest may explain the predominance of G2 arrest after adriamycin treatment in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567715     DOI: 10.1016/s0014-5793(99)01481-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.

Authors:  Changjun He; Xue-Pu Sun; Haiquan Qiao; Xian Jiang; Dongdong Wang; Xiangguo Jin; Xuesong Dong; Jizhou Wang; Hongchi Jiang; Xueying Sun
Journal:  Cancer Sci       Date:  2012-01-13       Impact factor: 6.716

2.  ELM1 is required for multidrug resistance in Saccharomyces cerevisiae.

Authors:  Abdul-Kader Souid; Chen Gao; Luming Wang; Elena Milgrom; W-C Winston Shen
Journal:  Genetics       Date:  2006-06-04       Impact factor: 4.562

3.  Critical differences between isoforms of securin reveal mechanisms of separase regulation.

Authors:  Xianxian Han; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2013-06-24       Impact factor: 4.272

4.  Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

Authors:  Shai J White; Laura M Kasman; Margaret M Kelly; Ping Lu; Laura Spruill; Paul J McDermott; Christina Voelkel-Johnson
Journal:  Free Radic Biol Med       Date:  2007-07-03       Impact factor: 7.376

5.  TBP-associated factor 1 overexpression induces tolerance to Doxorubicin in confluent H9c2 cells by an increase in cdk2 activity and cyclin E expression.

Authors:  Nicolas Servant; Daniela Marcantonio; John P H Th'ng; Lorraine E Chalifour
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

6.  Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism.

Authors:  Mirth T Hoyt; Rahul Palchaudhuri; Paul J Hergenrother
Journal:  Invest New Drugs       Date:  2010-02-20       Impact factor: 3.850

7.  Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress.

Authors:  Nidhi Bansal; Rama Kadamb; Shilpi Mittal; Leena Vig; Raisha Sharma; Bilikere S Dwarakanath; Daman Saluja
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

8.  βTrCP controls the lysosome-mediated degradation of CDK1, whose accumulation correlates with tumor malignancy.

Authors:  Joaquín Herrero-Ruiz; Mar Mora-Santos; Servando Giráldez; Carmen Sáez; Miguel A Japón; Maria Tortolero; Francisco Romero
Journal:  Oncotarget       Date:  2014-09-15

9.  Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.

Authors:  Marie Morfouace; Birgit Nimmervoll; Nidal Boulos; Yogesh T Patel; Anang Shelat; Burgess B Freeman; Giles W Robinson; Karen Wright; Amar Gajjar; Clinton F Stewart; Richard J Gilbertson; Martine F Roussel
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

10.  Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

Authors:  S M Harris; P Mistry; C Freathy; J L Brown; P A Charlton
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.